Journal
PAIN
Volume 111, Issue 1-2, Pages 169-180Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.pain.2004.06.015
Keywords
nociception; osteolysis; mouse; sarcoma
Categories
Funding
- NIDA NIH HHS [DA11986] Funding Source: Medline
- NIDCR NIH HHS [1F30-DE01471-01A1, 5 K16 DE00270-12] Funding Source: Medline
- NINDS NIH HHS [NS23970] Funding Source: Medline
Ask authors/readers for more resources
Patients with metastatic breast, lung or prostate cancer frequently have significant bone cancer pain. In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis. Following injection and confinement of green fluorescent protein-transfected murine osteolytic tumor cells into the marrow space of the femur of male C3H/HeJ mice, alendronate was administered chronically from the time the tumor was established until the bone cancer pain became severe. Alendronate therapy reduced ongoing and movement-evoked bone cancer pain, bone destruction and the destruction of sensory nerve fibers that innervate the bone. Whereas, alendronate treatment did not change viable tumor burden, both tumor growth and tumor necrosis increased. These data emphasize that it is essential to utilize a model where pain, skeletal remodeling and tumor growth can be simultaneously assessed, as each of these can significantly impact patient quality of life and survival. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available